FORM	4

(Print or Type Pernonses)

Check this l	oox if no
longer subje	ect to
Section 16.	Form 4 or
Form 5 obli	gations
may continu	ie. See
Instruction	1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Ations *See* b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person – Brandt Peter C.]	2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			
(Last) (First) C/O REXAHN PHARMACEUTICAL INC., 15245 SHADY GROVE ROAD,	S, (3. Date of Earliest Transaction (Month/Day/Year) 04/11/2017					her (specify belo	w)			
(Street) ROCKVILLE, MD 20850	4	4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
(Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if	Code (Instr. 8)	Code (A) or Disposed of (D)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained SEC 1474 (9-02) in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

	(e.g., puts, calls, warrants, options, convertible securities)														
1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Number of 6. Date Exercisable and		7. Title and Amount 8. Pr		8. Price of	9. Number of	10.	11. Nature		
Derivative	Conversion	Date	Execution Date, if	Transact	ion	Derivative	e	Expiration Da	ite	of Underlying De		Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)		Code		Securities (Month/Day/Year) S		Securities	ties Security		Securities	Form of	Beneficial		
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8))	Acquired			(Instr. 3 and 4) (Instr. 3		(Instr. 5)	~	Derivative	1	
	Derivative					or Dispos	ed					Security:	(Instr. 4)		
	Security					of (D)						Direct (D)			
						(Instr. 3, 4	Ι,				· · · · · ·	or Indirect			
						and 5)	1		1				Transaction(s) (Instr. 4)	· /	
											Amount		(Instr. 4)	(Instr. 4)	
									Expiration	Title	or				
				C. I.	v	(• >			Date		Number				
				Code	v	(A)	(D)				of Shares				
Stock															
Option	\$ 0.618	04/11/2017		А		110.000		04/11/2018	04/11/2027	Common Stock	110.000	\$ 0	110,000	D	
(right to	\$ 0.018	04/11/201/		л		110,000		04/11/2018	04/11/2027	Stock	110,000	50	110,000	D	
buy)															

Reporting Owners

Demonstrate Operation Names (Address		Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Brandt Peter C. C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850	х							

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for Peter C. Brandt	04/12/2017
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.